ELI LILLY CANADA INC
🚨 Critical Risk
FEI: 3016973244 • Toronto, ON • CANADA
FEI Number
3016973244
Location
Toronto, ON
Country
CANADAAddress
130 King St, Suit 900, Toronto, ON, Canada
Critical Risk
FDA Import Risk Assessment
This firm has an extensive history of FDA import refusals with severe violations.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
AGRINSULIN
The article appears to be composed wholly or partly of insulin manufactured in the US and offered for import by other than the manufacturer and reimportation does not appear to have been authorized by the Secretary for a medical emergency
INCONSPICU
Information required by the Act to be on the label or labeling does not appear to be conspicuous enough as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.
NEW VET DR
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the Federal Food, Drug, and Cosmetic Act in that it appears to be a new animal drug that is unsafe within the meaning of Section 512(a) of the Federal Food, Drug, and Cosmetic Act as it is not the subject of an approved new animal drug application, conditionally approved new animal drug application, or index listing, and no investigational new animal drug exemption applies.
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 12/22/2025 | 61PCL74TIRZEPATIDE (ANTI-DIABETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/10/2025 | 61PCK74TIRZEPATIDE (ANTI-DIABETIC) | Division of Southeast Imports (DSEI) | |
| 12/9/2025 | 61PCY74TIRZEPATIDE (ANTI-DIABETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/8/2025 | 58HCP09INSULIN GLARGINE | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/5/2025 | 61PCY74TIRZEPATIDE (ANTI-DIABETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/2/2025 | 61PCY74TIRZEPATIDE (ANTI-DIABETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 11/21/2025 | 58HCC06DULAGLUTIDE | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 11/14/2025 | 80FMFSYRINGE, PISTON | 336INCONSPICU | Division of Southeast Imports (DSEI) |
| 11/14/2025 | 58HCP09INSULIN GLARGINE | 72NEW VET DR | Division of Southeast Imports (DSEI) |
| 3/4/2025 | 58MDY11IXEKIZUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/4/2025 | 58MDY11IXEKIZUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/4/2025 | 58MCY11IXEKIZUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/4/2025 | 58MCY11IXEKIZUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/4/2025 | 58MCY11IXEKIZUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/4/2025 | 58MCY11IXEKIZUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/27/2025 | 58MCY11IXEKIZUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/21/2025 | 58MDY11IXEKIZUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/13/2025 | 58ODY06GUSELKUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/31/2025 | 62NCL99ANTI-PSORIATIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/31/2025 | 58MCK11IXEKIZUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/23/2025 | 66VCA99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/21/2025 | 61PCY58INSULIN LISPRO PROTAMINE (ANTI-DIABETIC) | Division of Southeast Imports (DSEI) | |
| 1/16/2025 | 61PCK74TIRZEPATIDE (ANTI-DIABETIC) | Division of Southeast Imports (DSEI) | |
| 1/7/2025 | 58MCY11IXEKIZUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/7/2025 | 58MDK11IXEKIZUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/6/2025 | 58MCY11IXEKIZUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/6/2025 | 58MDK11IXEKIZUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/6/2025 | 58MDK11IXEKIZUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/6/2025 | 58MDK11IXEKIZUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/6/2025 | 58MDK11IXEKIZUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/6/2025 | 58MDK11IXEKIZUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/30/2024 | 61PCL74TIRZEPATIDE (ANTI-DIABETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/10/2024 | 58MCK11IXEKIZUMAB | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/8/2024 | 61PCY17INSULIN (INJ) (ANTI-DIABETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/24/2024 | 61PCK19ISOPHANE INSULIN (SUSP) (ANTI-DIABETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/12/2024 | 61PCY17INSULIN (INJ) (ANTI-DIABETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/11/2024 | 61PDA17INSULIN (INJ) (ANTI-DIABETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/5/2024 | 61PCP54LISPRO INSULIN (ANTI-DIABETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/21/2021 | 66SDY51TADALAFIL | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
Frequently Asked Questions
What is ELI LILLY CANADA INC's FDA import refusal history?
ELI LILLY CANADA INC (FEI: 3016973244) has 39 FDA import refusal record(s) in our database, spanning from 4/21/2021 to 12/22/2025.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. ELI LILLY CANADA INC's FEI number is 3016973244.
What types of violations has ELI LILLY CANADA INC received?
ELI LILLY CANADA INC has been cited for 5 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about ELI LILLY CANADA INC come from?
All FDA import refusal data for ELI LILLY CANADA INC is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.